Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.38 |
| ▸ | FGF1 | P05230 | 3/20 | 0.32 |
| ▸ | FGF2 | P09038 | 3/20 | 0.32 |
| ▸ | VEGFA | P15692 | 3/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344916 | 1.00 | GBA1 (0.38) | GBA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL6574204 | 0.85 | GBA1 (0.46) | GBA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL6574209 | 0.85 | GBA1 (0.46) | GBA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL8992926 | 0.85 | GBA1 (0.46) | GBA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL3345071 | 0.80 | GJB2 (0.41) | GBA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL3345069 | 0.80 | GJB2 (0.41) | GBA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL8992782 | 0.79 | TNF (0.46) | GBA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL8992784 | 0.79 | TNF (0.46) | GBA1FGF1FGF2VEGFAHPSE | |
| SCHEMBL7594906 | 0.75 | ALDH1A1 (0.36) | GBA1TNF | |
| SCHEMBL12480998 | 0.75 | SLC2A1 (0.40) | GBA1TNFSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101595117-B | Method for production of furanose derivative | API CORP | 2014-01-22 | — | — | CN | disclosed |
| US-8394935-B2 | Method for producing furanose derivative | API CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8394935-B2 | Method for producing furanose derivative | API CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20100105890-A1 | METHOD FOR PRODUCING FURANOSE DERIVATIVE | API CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105890-A1 | METHOD FOR PRODUCING FURANOSE DERIVATIVE | API CORPORATION (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2105445-A1 | METHOD FOR PRODUCTION OF FURANOSE DERIVATIVE | API Corporation (JP) | 2009-09-30 | — | — | EP | disclosed |
| EP-2105445-A1 | METHOD FOR PRODUCTION OF FURANOSE DERIVATIVE | API Corporation (JP) | 2009-09-30 | — | — | EP | disclosed |
| WO-2008069303-A1 | METHOD FOR PRODUCTION OF FURANOSE DERIVATIVE | API CORPORATION (JP) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105890-A1 | METHOD FOR PRODUCING FURANOSE DERIVATIVE | DERA, ALDOA, DPYD | GBA1 1692/4885FGF1 1862/4885FGF2 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.